BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lin TC, Yoshida K, Tedeschi SK, de Abreu MM, Hashemi N, Solomon DH. Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2018;70:724-731. [PMID: 28834412 DOI: 10.1002/acr.23346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Palleria C, Iannone L, Leporini C, Citraro R, Manti A, Caminiti M, Gigliotti P, Grembiale RD, L'Andolina M, Muccari G, Naturale MD, Olivo D, Pagano Mariano G, Pellegrini R, Varcasia G, Abdalla K, Russo E, Ursini F, De Sarro G. Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP). PLoS One 2018;13:e0205134. [PMID: 30356301 DOI: 10.1371/journal.pone.0205134] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Wu YL, Ke J, Zhang BY, Zhao D. Hepatitis B virus reactivation in rheumatoid arthritis. World J Clin Cases 2022; 10(1): 12-22 [DOI: 10.12998/wjcc.v10.i1.12] [Reference Citation Analysis]
3 Huang SC, Cheng PN, Liu CH, Yang HC, Su TH, Tseng TC, Chen PJ, Kao JH, Liu CJ. Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents. J Formos Med Assoc 2021:S0929-6646(21)00424-1. [PMID: 34538552 DOI: 10.1016/j.jfma.2021.09.002] [Reference Citation Analysis]
4 Akiyama S, Cotter TG, Sakuraba A. Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics. World J Gastroenterol 2021; 27(19): 2312-2324 [PMID: 34040324 DOI: 10.3748/wjg.v27.i19.2312] [Reference Citation Analysis]
5 Patterson S, Schmajuk G, Evans M, Aggarwal I, Izadi Z, Gianfrancesco M, Yazdany J. Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications. Jt Comm J Qual Patient Saf 2019;45:348-57. [PMID: 30686706 DOI: 10.1016/j.jcjq.2018.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
6 Cheah JT, Faragon JJ, Marks KM. Management of hepatitis B and C infections in rheumatologic disease. Best Pract Res Clin Rheumatol 2018;32:848-68. [PMID: 31427059 DOI: 10.1016/j.berh.2019.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Zabotti A, Goletti D, Lubrano E, Cantini F. The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis. Expert Opin Drug Saf 2020;19:69-82. [PMID: 31847608 DOI: 10.1080/14740338.2020.1703946] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Huang SC, Yang HC, Kao JH. Hepatitis B reactivation: diagnosis and management. Expert Rev Gastroenterol Hepatol 2020;14:565-78. [PMID: 32448008 DOI: 10.1080/17474124.2020.1774364] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
9 Lai JH, Ling XC, Ho LJ. Useful message in choosing optimal biological agents for patients with autoimmune arthritis. Biochem Pharmacol 2019;165:99-111. [PMID: 30876919 DOI: 10.1016/j.bcp.2019.03.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Mok CC. Hepatitis B and C infection in patients undergoing biologic and targeted therapies for rheumatic diseases. Best Pract Res Clin Rheumatol 2018;32:767-80. [PMID: 31427054 DOI: 10.1016/j.berh.2019.03.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
11 Laserna A, Durán-Crane A, López-Olivo MA, Cuenca JA, Fowler C, Díaz DP, Cardenas YR, Urso C, O'Connell K, Fowler C, Price KJ, Sprung CL, Nates JL. Pain management during the withholding and withdrawal of life support in critically ill patients at the end-of-life: a systematic review and meta-analysis. Intensive Care Med 2020;46:1671-82. [PMID: 32833041 DOI: 10.1007/s00134-020-06139-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Zhong Z, Liao W, Dai L, Feng X, Su G, Gao Y, Wu Q, Yang P. Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection. Ann Rheum Dis 2021:annrheumdis-2021-221650. [PMID: 34933869 DOI: 10.1136/annrheumdis-2021-221650] [Reference Citation Analysis]
13 Wroński J, Fiedor P. The Safety Profile of Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis: Are TNF Inhibitors Safer Than We Thought? J Clin Pharmacol 2019;59:445-62. [PMID: 30476367 DOI: 10.1002/jcph.1348] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
14 Liu C, Shih YF, Liu CJ. Immunopathogenesis of Acute Flare of Chronic Hepatitis B: With Emphasis on the Role of Cytokines and Chemokines. Int J Mol Sci 2022;23:1407. [PMID: 35163330 DOI: 10.3390/ijms23031407] [Reference Citation Analysis]
15 Chen YM, Chen HH, Huang WN, Chen YH, Hsieh TY, Yang SS, Lan JL, Chen DY. Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation. Int J Rheum Dis 2019;22:1145-51. [PMID: 31117160 DOI: 10.1111/1756-185X.13582] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]